Natera, Inc. (NASDAQ:NTRA) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET

Company Participants

Michael Brophy - Chief Financial Officer

Steve Chapman - Chief Executive Officer

Solomon Moshkevich - President of Clinical Diagnostics

Alexey Aleshin - General Manager, Oncology & Chief Medical Officer

Conference Call Participants

Tejas Savant - Morgan Stanley

Puneet Souda - Leerink Partners

Catherine Schulte - Baird

Rachel Vatnsdal - JPMorgan

Dan Brennan - TD Cowen

Operator

Thank you for standing by and welcome to the Natera Inc. Q3 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] As a reminder today's call is being recorded.

I will now hand today's call over to Michael Brophy, Chief Financial Officer. Please go ahead sir.

Michael Brophy

Thanks operator. Good afternoon. Thank you for joining our conference call to discuss the results of our third quarter 2023. On the line I am joined by Steve Chapman, our CEO; Solomon Moshkevich, President of Clinical Diagnostics; and Alexey Aleshin, General Manager of Oncology and Chief Medical Officer. John Fesko, President and Chief Business Officer is also on the call and will be available for Q&A.

Today's conference call is being broadcast live via webcast. We will be referring to a slide presentation that has been posted investor.natera.com. A replay of the call will also be posted to our IR site as soon as it's available.

Starting on Slide 2. During the course of this conference call, we will make forward-looking statements regarding future events and our anticipated future performance such as our operational and finance outlook and projections, our assumptions for that outlook, market size, partnerships, clinical studies, opportunities and strategies, and expectations for various current and future products including product capabilities, expected to release dates, reimbursement coverage, and related effects on our financial and operating results.

We caution you that such statements reflect our best judgment based on factors currently known to us and that actual events or results could differ materially. Please refer to the documents we file from time-to-time with the SEC, including our most recent Form 10-K or 10-Q and the Form 8-K filed with today’s press release.

Those documents identify important risks and other factors that may cause our actual results to differ materially from those contained in or suggested by the forward-looking statements.

Forward-looking statements made during the call are being made as of today, November 8th, 2023. If this call is replayed or reviewed later after today, the information presented during the call may not contain current or accurate information. Natera disclaims any obligation to update or revise any forward-looking statements.